Omeros Corporation – Product Pipeline Review

Global Markets Direct’s, ‘Omeros Corporation – Product Pipeline Review – 2016’, provides an overview of the Omeros Corporation’s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Omeros Corporation, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.


The report provides a snapshot of the pipeline therapeutic landscape of Omeros Corporation

The report provides overview of Omeros Corporation including its business description, key facts, and locations and subsidiaries

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report assesses Omeros Corporation’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report features Omeros Corporation’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

Evaluate Omeros Corporation’s strategic position with total access to detailed information on its product pipeline

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Omeros Corporation

Identify potential new clients or partners in the target demographic

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Omeros Corporation’s pipeline depth and focus of pipeline therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 5

Omeros Corporation Snapshot 6

Omeros Corporation Overview 6

Key Information 6

Key Facts 6

Omeros Corporation - Research and Development Overview 7

Key Therapeutic Areas 7

Omeros Corporation - Pipeline Review 14

Pipeline Products by Stage of Development 14

Pipeline Products - Monotherapy 15

Omeros Corporation - Pipeline Products Glance 16

Omeros Corporation - Late Stage Pipeline Products 16

Omeros Corporation - Clinical Stage Pipeline Products 17

Omeros Corporation - Early Stage Pipeline Products 18

Omeros Corporation - Drug Profiles 22

OMS-721 22

OMS-405 24

OMS-824 25

Monoclonal Antibodies for Oncology, Metabolic, Cardiovascular and Musculoskeletal Disorders 26

Monoclonal Antibodies to Inhibit MASP-2 for Rheumatoid Arthritis and Diabetic Complications 28

OMS-527 30

OMS-616 32

OMS-906 34

Small Molecule to Agonize GPR52 for Schizophrenia 35

Small Molecule to Agonize PTH-1R for Osteoporosis 36

Small Molecule to Antagonize GPR101 for Appetite Disorders 37

Small Molecule to Antagonize GPR12 for Obesity, Cognitive Impairments and Motor Disorders 38

Small Molecule to Antagonize GPR139 for Motor Disorders 39

Small Molecule to Antagonize GPR15 for Rheumatoid Arthritis and HIV-Mediated Enteropathy 40

Small Molecule to Antagonize GPR161 for Oncology, Ophthalmology and Central Nervous System Disorders 41

Small Molecule to Antagonize GPR17 for Central Nervous System Disorders 42

Small Molecule to Antagonize GPR173 for Obesity and Schizophrenia 43

Small Molecule to Antagonize GPR182 for Pancreatic Cancer 44

Small Molecule to Antagonize GPR19 for Metastatic Melanoma and Lung Cancer 45

Small Molecule to Antagonize GPR20 for Gastro-Intestinal Stromal Tumors and Acute Myeloid Leukemia 46

Small Molecule to Antagonize GPR27 for Obesity, Diabetes and Schizophrenia 47

Small Molecule to Antagonize GPR31 for Anxiety Disorders 48

Small Molecule to Antagonize GPR39 for Esophageal Squamous Cell Carcinoma and Obesity-Related Type-2 Diabetes 49

Small Molecule to Antagonize GPR78 for Bipolar Disorder and Schizophrenia 50

Small Molecule to Antagonize GPR85 for Obesity and Schizophrenia 51

Small Molecule to Antagonize GPR87 for Oncology 52

Small Molecule to Antagonize NMUR2 for Pain 53

Small Molecule to Antagonize OPN4 for Circadian Rhythm Irregularities and Sleep Disorders 55

Small Molecule to Antagonize P2Y8 for Acute Lymphoblastic Leukemia and Lymphoma 56

Small Molecule to Inhibit CCRL2 for Rheumatoid Arthritis and Immune Disorders 57

Small Molecule to Target GPR132 for Cardiovascular Diseases 58

Small Molecule to Target GPR135 59

Small Molecule to Target GPR141 for Respiratory and Immune Disorders 60

Small Molecule to Target GPR150 for Ovarian Cancer 61

Small Molecule to Target GPR151 for CNS Diseases 62

Small Molecule to Target GPR153 for Schizophrenia 63

Small Molecule to Target GPR162 for Neuropsychiatric Disorders 64

Small Molecule to Target GPR171 for Eating and Hematological Disorders 65

Small Molecule to Target GPR174 for Immunology, Neurology and Oncology 66

Small Molecule to Target GPR183 for Osteoporosis and Epstein-Barr Viral Infections 67

Small Molecule to Target GPR21 for Obesity and Diabetes 68

Small Molecule to Target GPR22 for Anxiety, Cardiovascular Diseases and Osteoarthritis 69

Small Molecule to Target GPR25 for Arterial Stiffness 70

Small Molecule to Target GPR32 for Acute Inflammation 71

Small Molecule to Target GPR37 for Parkinson's Disease 72

Small Molecule to Target GPR37L1 for Hypertension and Cardiac Hypertrophy 73

Small Molecule to Target GPR45 74

Small Molecule to Target GPR50 for CNS and Metabolic Disorders 75

Small Molecule to Target GPR63 for Autism 76

Small Molecule to Target GPR65 for Oncology and Inflammatory Disorders 77

Small Molecule to Target GPR80 for Hepatocellular Carcinoma 78

Small Molecule to Target GPR82 for Appetite Disorders and Body Weight 79

Small Molecule to Target GPR83 for CNS and Immunological Disorders 80

Small Molecule to Target LGR4 for Oncology and Osteoporosis 81

Small Molecule to Target LGR5 for Esophageal Adenocarcinoma 82

Small Molecule to Target LGR6 for Dermatology 83

Small Molecule to Target MAS1 for Cognitive Impairments, Blood Pressure Abnormalities and Colon Cancer 84

Small Molecule to Target MRGE for Pain 85

Small Molecule to Target MRGF 86

Small Molecule to Target OGR1 for Oncology, Bone Diseases, Asthma and Osteoporosis 87

Small Molecule to Target OPN5 88

Small Molecules to Agonize GPR61 for Eating Disorder 89

Small Molecules to Target GPR146 for Metabolic Disorders 90

Omeros Corporation - Pipeline Analysis 91

Omeros Corporation - Pipeline Products by Target 91

Omeros Corporation - Pipeline Products by Route of Administration 94

Omeros Corporation - Pipeline Products by Molecule Type 95

Omeros Corporation - Pipeline Products by Mechanism of Action 96

Omeros Corporation - Recent Pipeline Updates 98

Omeros Corporation - Dormant Projects 107

Omeros Corporation - Discontinued Pipeline Products 108

Discontinued Pipeline Product Profiles 108

Omeros Corporation - Locations And Subsidiaries 109

Head Office 109

Other Locations & Subsidiaries 109

Appendix 110

Methodology 110

Coverage 110

Secondary Research 110

Primary Research 110

Expert Panel Validation 110

Contact Us 110

Disclaimer 111

List of Tables

List of Tables

Omeros Corporation, Key Information 10

Omeros Corporation, Key Facts 10

Omeros Corporation – Pipeline by Indication, 2016 12

Omeros Corporation – Pipeline by Stage of Development, 2016 18

Omeros Corporation – Monotherapy Products in Pipeline, 2016 19

Omeros Corporation – Phase III, 2016 20

Omeros Corporation – Phase II, 2016 21

Omeros Corporation – Preclinical, 2016 22

Omeros Corporation – Discovery, 2016 25

Omeros Corporation – Pipeline by Target, 2016 95

Omeros Corporation – Pipeline by Route of Administration, 2016 98

Omeros Corporation – Pipeline by Molecule Type, 2016 99

Omeros Corporation – Pipeline Products by Mechanism of Action, 2016 101

Omeros Corporation – Recent Pipeline Updates, 2016 102

Omeros Corporation – Dormant Developmental Projects,2016 111

Omeros Corporation – Discontinued Pipeline Products, 2016 112

Omeros Corporation, Subsidiaries 113

List of Figures

List of Figures

Omeros Corporation – Pipeline by Top 10 Indication, 2016 12

Omeros Corporation – Pipeline by Stage of Development, 2016 18

Omeros Corporation – Monotherapy Products in Pipeline, 2016 19

Omeros Corporation – Pipeline by Top 10 Target, 2016 95

Omeros Corporation – Pipeline by Route of Administration, 2016 98

Omeros Corporation – Pipeline by Molecule Type, 2016 99

Omeros Corporation – Pipeline Products by Top 10 Mechanism of Action, 2016 100


Discounts available for multiple report purchases.
+44 (0) 161 359 5414

Saved reports